Locus Pharmaceuticals have acquired the drug discovery company
Protein Mechanics, which brings together novel technologies that
broaden the scope of drug targets and further strengthens its
position as a leading company in computational...
The discovery of the three-dimensional structure of the anthrax
toxin as it binds to and enters human cells could lead to both a
treatment for the disease and a way to harness its effects in
cancer therapy, according to a report in...
Invitrogen subsidiary Protometrix is gearing up to launch a
microarray containing nearly all the 6,200 or so proteins in the
proteome of the yeast Saccharomyces cerevisiae, a commonly
used organism in genomics research.
Belgium's Opperbas Holding has started a mid-stage clinical trial
of a new formulation of factor VIII - used to treat haemophilia A -
that should cut the number of injections that sufferers of the
bleeding disease need to endure.
RNA interference is a promising new treatment approach for a range
of diseases, but delivering the RNAi compounds to the right
location has been a major obstacle to their development. Now, US
researchers have succeeded in getting...
Swiss contract manufacturing company Lonza has licensed a
technology that makes it possible to make peptide drugs that are
longer and have a more complex structure than is possible using
conventional techniques, reports Phil Taylor.
Germany's atugen, a specialist in RNA interference technologies for
switching off genes, has demonstrated the feasiblity of delivering
a small interfering RNA (siRNA)-based drug and achieving a
physiological response in animals.
A US company is gearing up to start trials of a novel drug that
could provide the first orally-active treatment for a range of
genetic disorders, including cystic fibrosis and muscular
dystrophy, writes Phil Taylor.